PMLS Virtual Series 2022 – Precision Pathology

On Demand Now Click Here

February 22, 2022

The winners in the world of pathology will be those who master technologies that generate results quickly and precisely.  Two broad technology domains dominate in pathology:  first, tissue-sample pathology methods that entail sample extraction and stabilization prior to analysis; and second, image analysis methods that enhance and enable pathologists to assess in vivo tissues and organs.

Imaging and non-imaging assays both have fleets of automated technologies designed for speed, volume, and accuracy.  Advances in analyzing samples and generating big data sets using classifiers, machine learning, and augmented intelligence allow for rapid quantification that match the large number of samples and images collected and catalogued for each patient.  Synergies of these technologies have enabled diagnoses at massive scale and in a timely manner every day.

The growing need for precision may, in fact, require both imaging and non-imaging assays, but will the time for a precise read-out override the need for a rapid decision on an efficacious treatment?  Have we reached the stage where assessment of a patient’s condition could be completed literally overnight?

Come join us at the Precision Pathology Virtual Summit to hear about the growing diversity and quality of pathology offerings in the precision medicine marketplace.  We have a roster of leaders from academia, biotech, pharmaceuticals, diagnostics, clinical research, healthcare and regulatory bodies who will address the following topics and more.

  • Emerging Assay platforms
  • Sample acquisition and stabilization techniques and kits
  • Informatics, Analytics, Signal and Image Processing
  • Genetics/Genomics
  • Proteomics/Protein-based Assays
  • Emerging ‘Omics Diagnostics
  • Gene and Protein Biomarkers
  • Augmented Intelligence – empowering the pathologist as partner with AI
  • Partnerships among clinical laboratories, imaging technology developers, pharmas, payers, and CROs – the technological, medical, and economic ecosystem to better healthcare

Who should attend:

  • Clinicians, pathologists, histologists, diagnostics developers, AI and system software designers, payers, research scientists, or in regulatory affairs
  • Executives and Decision Makers – CEOs, CFOs, CTOs, CMOs, and CSOs
  • Payers and Insurers
  • Medical and Pharmacy Directors
  • Employer and Retiree Benefits Analysts
  • Research, Development, and Practicing Clinicians
  • Diagnostics Developers
  • Diagnostics Licensing, Sales, and Planning
  • Regulatory Leaders in Government and Business Affairs groups
  • Economic Planners and Forecasters
  • Marketing Leaders
  • Systems Developers for Systems and Software
  • Artificial and Augmented Intelligence Developers
  • Emerging ‘Omics Diagnostics in Genetics/Genomics, Proteomics/Protein-based Assays
  • Imaging label developers
  • Biomarker Research Scientists and Developers
  • Imaging platforms
  • Artificial/Augmented Intelligence, Informatics, Analytics, Signal and Image Processing